3）Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42(13): 1129-40.4）Souza E, Crass RL, Felton J, Hanaya K, Pai MP. Accumulation of major linezolid metabolites in patients with renal impairment. Antimicrob Agents Chemother 2020; 64: e00027-20.5）Sato Y, Iguchi M, Kato Y, Morioka H, Hirabayashi A, Tetsuka N, et al. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days. Nagoya J Med Sci 2020; 82(3): 407-14.6）Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 2015; 70(1): 198-206.1）Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17(3): 382-7.2）Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42(1): 66-72.7）Hiramatsu S, Ikemura K, Fujisawa Y, Iwamoto T, Okuda M. Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharm Drug Dispos 2020; 41(6): 239-47.8）Ikemura K, Hamada Y, Kaya C, Enokiya T, Muraki Y, Nakahara H, et al. Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral human organic anion transporter 3. Drug Metab Dispos 2016; 44(10): 1543-9.9）Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29(8): 1136-45.10）Zou L, Matsson P, Stecula A, Ngo HX, Zur AA, Giacomini KM. Drug metabolites potently inhibit renal organic anion transporters, OAT1 and OAT3. J Pharm Sci 2021; 110(1): 347-53.11）Parvez MM, Kaisar N, Shin HJ, Jung JA, Shin JG. Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A Family. Antimicrob Agents Chemother 2016; 60(11): 6558-67.12）Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J Infect Chemother 2011; 17(3): 388-91.13）Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, et al. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 2001; 57(6-7): 485-92.14）McCallum MM, Pawlak AJ, Shadrick WR, Simeonov A, Jadhav A, Yasgar A, et al. A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding. Anal Bioanal Chem 2014; 406(7): 1867-75.15）Sakurai N, Kawaguchi H, Abe J, Kuwabara G, Imoto W, Shibata W, et al. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients. Pharmacotherapy 2022; 42(9): 707-15.101文 献
元のページ ../index.html#115